DGAP-Adhoc: Merck KGaA: Merck and GSK agree on Collaboration in Immuno-Oncology
- 161
|
DGAP-Ad-hoc: Merck KGaA / Key word(s): Alliance Merck KGaA and GlaxoSmithKline plc (GSK) will collaborate closely in the field of immuno-oncology. The cooperation relates to M7824, a bifunctional fusion protein developed by Merck. This is currently in clinical development and targets various forms of cancer that are difficult to treat.
Merck will receive an upfront payment of EUR300 million and is eligible for potential development milestone payments of up to EUR500 million. Merck will also be eligible for further payments upon successfully achieving future approval and commercial milestones of up to EUR2.9 billion. The total potential deal value is up to EUR3.7 billion. The two companies will jointly develop and commercialize M7824. All profits and costs from the collaboration will be shared equally on a global basis. In total, eight high priority clinical development studies for M7824 are ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers. Contact: Friederike Segeberg, Head of Media Relations
05-Feb-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Merck KGaA |
| Frankfurter Str. 250 | |
| 64293 Darmstadt | |
| Germany | |
| Phone: | +49 (0)6151 72 - 6328 |
| Fax: | +49 (0)6151 72 - 3183 |
| E-mail: | [email protected] |
| Internet: | www.merck.de |
| ISIN: | DE0006599905 |
| WKN: | 659990 |
| Indices: | DAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX |
| End of Announcement | DGAP News Service |
|
|
772413 05-Feb-2019 CET/CEST
EQS Group is a leading international technology provider for Digital Investor Relations, Corporate Communications and Compliance. More than 8,000 companies worldwide trust EQS’s products and services to securely, efficiently, and simultaneously fulfil complex national and international disclosure and compliance requirements, and to reach stakeholders globally.
